BioSpace News Archive

Dr. Gerard A. Silvestri of Medical University of South Carolina Named Principal Investigator

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. ET.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into an agreement with the United States Government to support the development, manufacture and initial distribution of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon approval or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the acquisition of OncoImmune,

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced their sponsorship of Donate Life at the annual Tournament of Roses® celebration.

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Dr. Michael Dunne has resigned from his role as Chief Scientific Officer of the Company, effective December 21, 2020.

The Company began enrolling patients in Saturn-1 in September 2020 and expects to initiate its second pivotal registration trial, Saturn-2, in 2021

Progressive Care Inc., a personalized healthcare services and technology company, is pleased to announce that the Company has completed its move into its new 11,000 sq ft pharmacy space in Hallandale Beach, FL.

It is with great excitement that APSA and Veritas Association Management announce the selection of Thomas F. Tracy, Jr., MD, MBA as the new Executive Director of the American Pediatric Surgical Association.

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress from its ongoing license agreement with AstraZeneca (LSE: AZN) (STO: AZN) (NASDAQ: AZN) under which the program has achieved a preclinical milestone.

DermOQ Inc., the oxygen skin care provider of Oxygen Lab™ topical skin care products to physician’s offices, spas, and aestheticians and Element Eight® prestige skin care announced today that it had closed the acquisition of ECHO2 Plus® and Oxyceuticals™ oxygen facial treatment product lines from Skin Products, Inc. for an undisclosed amount.